NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Neurotrope,
Inc. (NASDAQ: NTRP), a clinical-stage biopharmaceutical
company developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease, today announced that Dr.
Charles Ryan, Neurotrope's Chief
Executive Officer, will present a company overview at the Ladenburg
Thalmann 2018 Healthcare Conference in New York on Tuesday,
October 2nd, 2018 at 9:30
a.m. Eastern Time.
A live webcast of the presentation will be available on the
"Events and Presentations" page in the "Investors and Media"
section of the Company's website at
http://www.neurotrope.com/. The presentation will be archived
on the Company's website and be available for replay for 90
days.
Below is a direct link to the live webcast:
http://wsw.com/webcast/ladenburg4/ntrp/
About Neurotrope
Neurotrope is at the forefront of developing a new approach to
combating AD and other neurodegenerative diseases. The
Company's world-class science offers the potential to realize a
paradigm shift to overcome one of today's most challenging clinical
problems — finding a way to slow or even prevent the progression of
AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
Bryostatin-1 as a potential treatment for Stroke, Traumatic Brain
Injury, and Fragile X Syndrome, and Niemann-Pick Type C disease —
rare genetic diseases for which only symptomatic treatments are
currently available. The FDA has granted Orphan Drug Designation to
Neurotrope for Bryostatin-1 as a treatment for Fragile
X. Bryostatin-1 has already undergone testing in more than
1,500 people in cancer studies, thus creating a large safety data
base that will further inform clinical trial designs.
Please visit www.neurotrope.com for further
information.
Contact information:
Sam Martin / Ryan Baker
Argot Partners
212.600.1902
neurotrope@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/neurotrope-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference-300720075.html
SOURCE Neurotrope, Inc.